Abstract
Objectives: Severe disease characterised by interstitial pneumonia may develop in some cases of coronavirus disease (COVID-19). Periostin has been associated with many respiratory diseases. In this study, we aimed to investigate whether periostin could be a useful new biomarker in the follow-up and severity assessment of the disease in patients with COVID-19 pneumonia.
Methods: In the study, 32 patients followed up during May to July 2020 because of COVID-19 and 24 healthy controls were included. The patients were divided into two groups, namely, mild/moderate and severe, according to the severity of the disease. Serum periostin and transforming growth factor beta (TGF-β) levels were tested using an enzyme-linked immunosorbent assay (ELISA) method using commercially available ELISA kits.
Results: It was observed that the periostin level was significantly higher in both mild/moderate cases and severe cases compared with the control group at first presentation. However, TGF-β levels at first presentation were similar between the groups.
Conclusions: The current manuscript may be the first one performing periostin ELISA on COVID serum, and we believe that periostin can be used as a new biomarker.
【초록키워드】 COVID-19, coronavirus disease, coronavirus, COVID-19 pneumonia, Biomarker, Pneumonia, severity, respiratory diseases, ELISA, COVID, serum, enzyme-linked immunosorbent assay, Patient, severe cases, Beta, Follow-up, interstitial pneumonia, respiratory, disease, TGF-β, severe disease, in some, transforming growth factor, control group, two groups, enzyme, healthy control, Severe case, growth factor, manuscript, ELISA kits, enzyme-linked immunosorbent, Periostin, tested, develop, the disease, can be used, significantly higher, groups, patients with COVID-19,